Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03021499 · ClinicalTrials.gov registry record · Phase 3
Aurinia Renal Response in Active Lupus With Voclosporin
A Phase 3 study of Lupus Nephritis, sponsored by Aurinia Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 358
- Enrollment target
- 20
- Study locations
NCT03021499 is a Phase 3 study of Lupus Nephritis that has completed, run by Aurinia Pharmaceuticals. The registered enrollment target is 358 participants, above the 298-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (20% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT03021499, a Phase 3 study of Lupus Nephritis, has completed, sponsored by Aurinia Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 358 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the efficacy of voclosporin compared with placebo in achieving renal response after 52 weeks of therapy in subjects with active lupus nephritis.
Conditions Studied
Interventions
- DRUG Placebo Oral Capsule
- DRUG Voclosporin
Study Locations (20)
Florida
- AURORA Investigative Center - Clearwater
- AURORA Investigative Center - DeBary
- AURORA Investigative Center - Fort Lauderdale
- AURORA Investigative Center - Fort Myers
- AURORA Investigative Center - Miami
- AURORA Investigative Center - Orlando
- AURORA Investigative Center - Winter Park
California
- AURORA Investigative Center - Beverly Hills
- AURORA Investigative Center - Los Angeles
- AURORA Investigative Center - Los Angeles
- AURORA Investigative Center - Palo Alto
- AURORA Investigative Center - Thousand Oaks
- AURORA Investigative Center - Torrance
Arizona
- AURORA Investigative Center - Phoenix
- AURORA Investigative Center - Phoenix
Colorado
- AURORA Investigative Center - Aurora
- AURORA Investigative Center - Denver
Alabama
- AURORA Investigative Center - Huntsville
Connecticut
- AURORA Investigative Center - New Haven
Georgia
- AURORA Investigative Center - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 358 participants |
| Start Date | 2017-05-17 |
| Est. Completion | 2019-10-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03021499
The ClinicalTrials.gov registry entry for NCT03021499 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 358 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 298-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (20% higher). The listed sponsor is Aurinia Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lupus Nephritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo Oral Capsule is the first listed.
NCT03021499 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT03021499 about?
NCT03021499 is a clinical study titled "Aurinia Renal Response in Active Lupus With Voclosporin". The purpose of this study is to assess the efficacy of voclosporin compared with placebo in achieving renal response after 52 weeks of therapy in subjects with active lupus nephritis.
What is the current status of trial NCT03021499?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 358 participants. The study started on 2017-05-17. Estimated completion is 2019-10-10.
What conditions does trial NCT03021499 study?
This clinical trial studies the following conditions: Lupus Nephritis.
What interventions are being tested in trial NCT03021499?
The interventions under investigation include: Placebo Oral Capsule (DRUG), Voclosporin (DRUG).
Who is sponsoring clinical trial NCT03021499?
This trial is sponsored by Aurinia Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03021499 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lupus Nephritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
RECRUITING · Phase 3
-
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis
COMPLETED · Phase 3
-
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
RECRUITING · Phase 2
-
The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.